Abstract
Background: Acute kidney injury (AKI) is a common and serious complication after noncardiac surgery. While levosimendan has shown renal protective effects in cardiac surgery patients, its impact in non-cardiac surgery – especially among patients with cardiovascular risk factors – remains unknown. Therefore, in this secondary analysis, we evaluated the effect of perioperative levosimendan administration on the incidence of postoperative AKI. We further assessed its impact on perioperative maximum creatinine concentration, estimated glomerular filtration rate (eGFR), and perioperative body composition parameters.Methods: We included all 228 patients from the main trial. Among these, 115 patients were assigned to receive a single dose of levosimendan, while113 patients were allocated to the placebo group. Blood samples and body composition parameters were assessed preoperatively, within one hour after surgery, and on the first, second, third and fifth postoperative day.Results: The incidence of postoperative AKI (p=0.485) did not differ significantly; also, the logistic regression model showed no significant treatment effect between the groups (OR 1.348, 95% CI 0.466 to 4.086; p=0.584). Maximum creatinine concentrations (effect estimate: 0.04 mg.dL-1, 95% CI -0.07 to 0.15; p=0.481), eGFR (effect estimate -1.01mL.min-1.BSA, 95% CI -6.98 to 4.97; p=0.743), and postoperative overhydration were also similar between the groups.Conclusion: Unlike findings in cardiac surgery patients, perioperative levosimendan administration did not provide renal protection in high-risk cardiovascular patients undergoing major noncardiac surgery.